

Fig. 1




Fig. 3





Fig. 4

Anti-E1 levels in NON-responders to IFN treatment

Series 1




weeks after start of treatment

Fig. 5

Anti-E1 levels in RESPONDERS to IFN treatment

SERIES 1




weeks after start of treatment

Fig. 6

Anti-E1 levels in patients with COMPLETE response to IFN

SERIES 2




months after start of treatment

Fig. 7

Anti-E1 levels in INCOMPLETE responders to IFN treatment

SERIES 2



months after start of treatment


Fig. 8



Fig. 9

Anti-E2 levels in RESPONDERS to IFN treatment

SERIES 1




weeks after start of treatment

Fig.10

Anti-E2 levels in INCOMPLETE responders to IFN treatment

SERIES 2



months after start of treatment

Fig.11

Anti-E2 levels in COMPLETE responders to IFN treatment

SERIES 2




Fig.12

Human anti-E1 reactivity competed with peptides




Fig.13

Competition of reactivity of anti-E1 Mabs with peptides





Fig. 14

Anti-E7 (epitope 1) levels in NON-RESPONDERS to IFN treatment



weeks after start of treatment

Fig.15

Anti-E1 (epitope 1) levels in RESPONDERS to IFN treatment




Fig.16

Anti-E1 (epitope 2) levels in NON-RESPONDERS to IFN treatment

SERIES 1





Fig.17


Anti-E1 (epitope 2) levels in RESPONDERS to IFN treatment



weeks after start of treatment

Fig.18

Figure 1 is a schematic representation of the experimental design. It shows a vertical timeline of events for two groups: 'Control' and 'Experimental'. The timeline starts with 'Baseline' and ends with 'Post-test'. The 'Control' group receives 'Control' treatment, while the 'Experimental' group receives 'Experimental' treatment. The 'Experimental' group also receives 'Control' treatment at a later point. The timeline is divided into 'Pre-test' and 'Post-test' phases. The 'Pre-test' phase includes 'Baseline' and 'Pre-test' measurements. The 'Post-test' phase includes 'Post-test' and 'Follow-up' measurements. The 'Experimental' group shows a significant improvement in 'Post-test' and 'Follow-up' measurements compared to the 'Control' group.



Human anti-E2 reactivity competed with peptides




Fig. 20

Fig. 21A

5' GGCATGCAAGCTTAATTAATT3' (SEQ ID NO 1)

3'ACGTCCGTACGTTTGAATTAATTAATCGA5' (SEQ ID NO 94)

5'CCGGGGAGGGCCTGCACGTGATCGAGGGCAGACACCATCACCACCATCACTAATAGT
TAATTAAGTCA 3' (SEQ ID NO 2)

3'CCTCCGGACGTGCACTAGCTCCCGTCTGTGGTAGTGGTGGTAGTGATTATCAATTAATTG
5' (SEQ ID NO 95)

SEQ ID NO 3 (HCC19A)

ATGCCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCTTTACTGTCTGTCTGACCATTCOA
GCTTCCGCTTATGAGGTGCGCAACGTGTCCGGGATGTACCATGTCACGAACGACTGCT
CCAACTCAAGCATTGTGTATGAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGT
GCCCTGCGTTCCGGGAGAACAACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTC
GCAGCTAGGAACGCCAGCGTCCCCACCACGACAATACGACGCCACGTGCAATTTGCTCG
TTGGGGCGGGCTGCTCTCTGTTCCGCTATGTACGTGGGGATCTCTGCGGATCTGTCTTC
CTCGTCTCCAGCTGTTCAACATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCA
ATTGCTCAATCTATCCCGGCCACATAACAGGTCACCGTATGGCTTGGGATATGATGAT
GAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCT
GTCGTGGACATGGTGGCGGGGGCCCATTTGGGGAGTCCTGGCGGGCCTCGCCTACTATT
CCATGGTGGGGAAGTGGGCTAAGGTTTTGATTGTGATGCTACTCTTTGCTCTCTAATAG

SEQ ID NO 5 (HCC110A)

ATGTTGGGTAAAGTCATCGATACCCTTACATGCCGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT
ATCTTCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGGC
CAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTGCAATTTGCTCGTTGGGGCGGGCTGCTTTCTG

Fig. 21B

TTCCGCTATGTACGTGGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCA
CCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGG
CCACATAACGGGTCACCGSTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACG
GCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCTGGACATGGTGGCGG
GGGCCCCATTGGGGAGTCTTGGCGGGTCTCGCCTACTATTCCATGGTGGGGAACTGGGC
TAAGGTTTTGATTGTGATGCTACTCTTTGCTCCCTAATAG

SEQ ID NO 7 (HCC111A)

ATGTTGGGTAAGGTCATCGATACCCCTTACGTGCGGGCTTCGCCGACCTCATGGGGTACA
TTCCGCTCGTCGGCGCCCCCTAGGGGGGTGCTGCCAGAGCCCTGGCGCATGGCGTCCG
GGTTCTGGAAGACGGCGTGAACATATGCAACAGGGAAATTTGCCTGGTTGCTCTTTCTCTA
TCTTCCTCTTGGCTTTACTGTCTGTCTGACCATTCCAGCTTCCGCTTATGAGGTGCGC
AACGTGTCCGGGATGTACCATGTACGAACGACTGCTCCAACCTCAAGCATTGTGTATG
AGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCCGGGAGAACA
ACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCGT
CCCCACTACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCGGGCTGCTTTCTGTT
CCGCTATGTACGTGGGGGATCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTACCC
ATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCC
ACATAACAGGTCACCGSTATGGCTTGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 9 (HCC112A)

ATGCCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCCCTGCTGTCTGTCTGACCATACCA
GCTTCCGCTTATGAAGTGCGCAACGTGTCCGGGGTGTACCATGTACGAACGACTGCT
CCAACCTCAAGCATAGTGTATGAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGT
GCCCTGCGTTCCGGAGGGCAACTCCTCCCGTTGCTGGGTGGCGCTCACTCCCACGCTC
GCGGCCAGGAACGCCAGCGTCCCCACAACGACAATACGACGCCACGTCGATTTGCTC
GTTGGGGCTGCTGCTTTCTGTTCCGCTATGTACGTGGGGGATCTCTGCGGATCTGTTTT
CCTTGTTTTCCAGCTGTTACCTTCTCACCTCGCCGGCATCAAACAGTACAGGACTGCA
ACTGCTCAATCTATCCCGGCCATGTATCAGGTCACCGCATGGCTTGGGATATGATGAT
GAACTGGTCCTAATAG

SEQ ID NO 11 (HCC113A)

ATGTCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCCCTGCTGTCTGTCTGACCATACCA
GCTTCCGCTTATGAAGTGCGCAACGTGTCCGGGGTGTACCATGTACGAACGACTGCT
CCAACCTCAAGCATAGTGTATGAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGT

Fig. 21C

GCCCTGCGTTGCGGAGGGCAACTCCTCCCGTTGCTGGGTGGCGCTCACTCCCACGCTC
GCGGCCAGGAACGCCAGCGTCCCCACAACGACAATACGACGCCACGTGATTTGCTC
GTTGGGGGCTGCTGCTTTCTGTTCCGCTATGTACGTGGGGGATCTCTGCGGATCTGTTTT
CCTTGTTTTCCAGCTGTTACCTTCTCACCTCGCCGGCATCAAACAGTACAGGACTGCA
ACTGCTCAATCTATCCCGGCCATGTATCAGGTCACCGCATGGCTTGGGATATGATGAT
GAACTGGTAATAG

SEQ ID NO 13 (HCC17A)

ATGCTGGGTAAGGCCATCGATACCCCTTACGTGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTGGCGCCCCCTAGGGGGCCCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAAGACGGCGTGAACATGCAACAGGGAATTTGCCTGGTTGCTCTTTCTCTA
TCTTCCTCTTGGCTTTACTGTCTGTCTAACCATTCCAGCTTCCGCTTACGAGGTGCGC
AACGTGTCCGGATGTACCATGTTCACGAACGACTGCTCCAACTCAAGCATTGTGTATG
AGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCCGGAGAACA
ACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCGGCTAGGAACGCCAGCAT
CCCCACTACAACAATACGACGCCACGTGATTTGCTCGTTGGGGCGGCTGCTTTCTGTT
CCGCTATGTACGTGGGGGATCTCTGCGGATCTGTCTTCCTCGTCTCCAGCTGTTACCC
ATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCC
ACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTACTAATAG

SEQ ID NO 15 (HCP51)

ATGCCCGGTTGCTCTTTCTCTATCTT

SEQ ID NO 16 (HCP52)

ATGTTGGGTAAGGTCATCGATACCCT

SEQ ID NO 17 (HCP53)

CTATTAGGACCAGTTCATCATCATATCCCA

SEQ ID NO 18 (HCP54)

CTATTACCAGTTCATCATCATATCCCA

SEQ ID NO 19 (HCP107)

ATACGACGCCACGTGATTCAGCTGTTACCATC

Fig. 21D

SEQ ID NO 20 (HCP108)

GATGGTGAACAGCTGGGAATCGACGTGGCGTCGTAT

SEQ ID NO 21 (HCC137)

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACATATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT
ATCTTCCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTACGAACGACTGCTCCAACCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCCGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTGATTCCCAGCTGTTACCATCTCGCCTCG
CCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGT
CACCGTATGGCTTGGGATATGATGATGAACTGGTCCCTACAACGGGCCCTGGTGGTAT
CGCAGCTGCTCCGATCCGACAAGCTGTCTGAGACATGGTGGCGGGGGCCCATTTGGGG
AGTCTGGCGGGTCTCCCTACTATTCCATGGTGGGGAACCTGGGCTAAGGTTTTGATTG
TGATGCTACTCTTTGCTCCCTAATAG

SEQ ID NO 23 (HCC138)

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACATATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT
ATCTTCCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTACGAACGACTGCTCCAACCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCCGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTGATTCCCAGCTGTTACCATCTCGCCTCG
CCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGT
CACCGTATGGCTTGGGATATGATGATGAACTGGTAA
TAG

SEQ ID NO 25 (HCC139)

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACATATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT

Fig. 21E

ATCTTCCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTACGAACGACTGCTCCAACTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTGCGATTCCCAGCTGTTACCATCTCGCCTCG
CCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGT
CACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTAT
CGCAGCTGCTCCGGATCCTCTAATAG

SEQ ID NO 27 (HCC140)

ATGTTGGGTAAAGGTCATCGATACCCCTTACATGCGGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCCGGCCCGCCCTAGGGGGCGCTGCCAGGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT
ATCTTCCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTACGAACGACTGCTCCAACTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTGCGATTCCCAGCTGTTACCATCTCGCCTCG
CCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGT
CACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTAT
CGCAGCTGCTCCGGATCCTGATCGAGGGCAGACACCATCACCACCATCACTAATAG

SEQ ID NO 29 (HCC162)

ATGGGTAAAGGTCATCGATACCCCTTACGTGCGGATTCCCGATCTCATGGGGTACATCC
CGCTCGTCCGGCGCTCCCGTAGGAGGCGTCGCAAGAGCCCTTGCGCATGGCGTGAGGGC
CCTTGAAGACGGGATAAATTTGCAACAGGGAATTTGCCCGGTTGCTCCTTTCTATTT
TCCTTCTCGCTCTGTTCTCTTGCTTAATTCATCCAGCAGCTAGTCTAGAGTGCGGGAAT
ACGTCTGGCCTCTATGTCCTTACCAACGACTGTTCCAATAGCAGTATTGTGTACGAGGC
CGATGACGTTATTCTGCACACACCCGGCTGCATACCTTGTGTCCAGGACGGCAATACA
TCCACGTGCTGGACCCCGAGTGACACCTACAGTGGCAGTCAAGTACGTCCGAGCAACCA
CCGCTTCGATACGCAGTCATGTGGACCTATTAGTGGGCGCGGCCACGATGTGCTCTGC
GCTCTACGTGGGTGACATGTGTGGGGCTGTCTTCCTCGTGGGACAAGCCTTCACGTTCA
GACCTCGTCGCCATCAAACGGTCCAGACCTGTAAGTCTCGCTGTACCCAGGCCATCT
TTCAGGACATCGAATGGCTTGGGATATGATGATGAACTGGTAATAG

Fig. 21F

SEQ ID NO 31 (HCC163)

ATGGGTAAGGTCATCGATACCCTAACGTGCGGATTGCGCGATCTCATGGGGTATATCC
CGCTCGTAGGCGGGCCCCATTGGGGGCGTCGCAAGGGCTCTCGCACACGGTGTGAGGGT
CCTTGAGGACGGGGTAACTATGCAACAGGGAATTTACCCGGTTGCTCTTTCTCTATCT
TTATTCTTGCTCTTCTCTCGTGTCTGACCGTTCCGGCCTCTGCAGTTCCTACCGAAATG
CCTCTGGGATTTATCATGTTACCAATGATTGCCCAAACCTCTTCCATAGTCTATGAGGCA
GATAACCTGATCCTACACGCACCTGGTTGCGTGCCTTGTGTCATGACAGGTAATGTGA
GTAGATGCTGGGTCCAAATTACCCCTACACTGTCAGCCCCGAGCCTCGGAGCAGTCAC
GGCTCCTCTTCGGAGAGCCGTTGACTACCTAGCGGGAGGGGGCTGCCCTCTGCTCCGCG
TTATACGTAGGAGACGCGTGTGGGGCACTATTCTTGGTAGGCCAAATGTTACCTATA
GGCCTCGCCAGCACGCTACGGTGCAGAACTGCAACTGTTCCATTTACAGTGGCCATGT
TACCGGCCACCGGATGGCATGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 33 (HCP109)

TGGGATATGATGATGAACTGGTC

SEQ ID NO 34 (HCP72)

CTATTATGGTGGTAAKGCCARCARCARGAGCAGGAG

SEQ ID NO 35 (HCOL22A)

TGGGATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTGCTCC
GGATCCCACAAGCTGTGCTGGACATGGTGGCGGGGGGCCCATTTGGGGAGTCTTGGCGG
GCCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTC
TTTGCCGGCGTCGACGGGCATACCCGCGTGTGAGGAGGGGCAGCAGCCTCCGATACCA
GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTGCGCTCAGAAAATCCAGCTCGTAAACAC
CAACGGCAGTTGGCACATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAAC
AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG
CGCTTGGCCAGCTGTGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCTCACTT
ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC
GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTAATTGCTTACCCCGAGCC
CTGTTGTGGTGGGGACGACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAA
CGACTCGGATGTGCTGATTCTCAACAACACGCGGCCGCGGAGGCAACTGGTTCCGGC
TGTACATGGATGAATGGCACTGGGTTCCACCAAGACGTGTGGGGGGCCCCCGTGAACA
TCGGGGGGGGCCGGCAACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCC
CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT

Fig. 21G

CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT
TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTTGAAGCCGCATGCAATTGGACTCG
AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG
TCTACAACAGAGTGGCAGATACTGCCCTGTTCTTACCACCCTGCCGGCCCTATCCA
CCGGCCTGATCCACCTCCATCAGAACATCGTGGACGTGCAATACCTGTACGGTGTAGG
GTCGGCGGTTGTCTCCCTTGTCTCAAATGGGAGTATGTCTGTTGCTCTTCTTCTCTCT
GGCAGACGCGCGCATCTGCGCCTGCTTATGGATGATGCTGCTGATAGCTCAAGCTGAG
GCCGCCTTAGAGAACCTGGTGGTCTCAATGCCGCGGCCGTGGCCGGGGCGCATGGC
ACTCTTTCTTCTTGTGTTCTTCTGTGCTGCCTGGTACATCAAGGGCAGGCTGGTCCC
TGGTGCGGCATACGCCTTCTATGGCGTGTGGCCGCTGCTCCTGCTTCTGCTGGCCTTAC
CACCACGAGCTTATGCCTAGTAA

SEQ ID NO 37 (HCC141)

GATCCCAACAAGCTGTCTGGACATGGTGGCGGGGGCCCATTTGGGGAGTCCTGGCGGG
CCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCT
TTGCCGGCGTCGACGGGCATACCGCGGTGTCAGGAGGGGCAGCAGCCTCCGATACCA
GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTGGGCTCAGAAAATCCAGCTCGTAAACAC
CAACGGCAGTTGGCACATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAAC
AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG
CGCTTGGCCAGCTGTGCTCCATCGACAAGTTGCTCAGGGGTGGGGTCCCTCACTT
AACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC
GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTACCCCCGAGCC
CTGTTGTGGTGGGGACGACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAA
CGACTCGGATGTGCTGATTCTCAACAACACGCGGCCGCGGAGGCAACTGGTTCGGC
TGTACATGGATGAATGGCACTGGGTTACCAAGACGTGTGGGGGGCCCCCGTGCAACA
TCGGGGGGGGCCGGCAACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCC
CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT
CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT
TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTTGAAGCCGCATGCAATTGGACTCG
AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG
TCTACAACAGAGTGGCAGAGTGGCAGAGCTTAATTAATTAG

SEQ ID NO 39 (HCC142)

GATCCCAACAAGCTGTCTGGACATGGTGGCGGGGGCCCATTTGGGGAGTCCTGGCGGG
CCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCT

Fig. 21H

TTGCCGGCGTCGACGGGCATACCCGCGTGTCTCAGGAGGGGCAGCAGCCTCCGATACCA
GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTGGGCTCAGAAAATCCAGCTCGTAAACAC
CAACGGCAGTTGGCACATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAAC
AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG
CGCTTGGCCAGCTGTGGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTT
ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC
GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC
CTGTTGTGGTGGGGACGACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAA
CGACTCGGATGTGCTGATTCTCAACAACACGCGCGCCGCGCAGGCAACTGGTTCGGC
TGTACATGGATGAATGGCACTGGGTTACCAAGACGTGTGGGGGGCCCCCGTGCAACA
TCGGGGGGGGCCGGCAACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCC
CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT
CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT
TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCSAAGCCGCATGCAATTGGACTCG
AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG
TCTACAACAGGTGATCGAGGGCAGACACCATCACCACCATCACTAATAG

SEQ ID NO 41 (HCC143)

ATGGTGGGGAACTGGGGCTAAGGTTTTGGTGTGATGCTACTCTTTGCCGGCGTCGACG
GGCATACCCGCGTGTCTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCT
CTTTAGCCCCGGGTGGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC
ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCA
TATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTG
CTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC
TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG
CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC
GACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTG
ATTCTCAACAACACGCGGCCGCGCGCAGGCAACTGGTTCGGCTGTACATGGATGAATG
GCACTGGGTTACCAAGACGTGTGGGGGGCCCCCGTGCAACATCGGGGGGGCCGGCA
ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCCGAGGCCACCTACGC
CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG
CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGG
GGGCGTGGAGCACAGGTTCSAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGA
CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGG
CAGAGCTTAATTAATTAG

Fig. 21I

SEQ ID NO 43 (HCC144)

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACG
GGCATACCCGCGTGTGAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCT
CTTTAGCCCCGGGTGGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC
ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC
TATTCTACAAACACAAATTCAACTCGTCTGGATGCCAGAGCGCTTGGCCAGCTGTG
CTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCTCACTTACACTGAGCCTAACAGC
TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG
CGTCTCAGGTGTGCGGTCCAGTGATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC
GACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTG
ATTCTCAACAACACGCGCGCGCGGAGGCAACTGGTTCGGCTGTACATGGATGAATG
GCACTGGGTTACCAAGACGTGTGGGGGCCCCCGTGCAACATCGGGGGGGCGCGCA
ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGGCCACCTACGC
CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG
CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGG
GGGCGTGGAGCACAGGTTGGAAGCCGCATGCAATTGGAATCGAGGAGAGCGTTGTGA
CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGGTGAT
CGAGGGCAGACACCATCACCACCATCACTAATAG

SEQ ID NO 45 (HCC164)

ATGGTGGCGGGGGGCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGG
GGAAGTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGGCATA
CCGCGTGTGAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGC
CCCGGGTGGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAAC
AGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCT
ACAAACACAAATTCAACTCGTCTGGATGCCAGAGCGCTTGGCCAGCTGTGCTCCAT
CGACAAGTTCGCTCAGGGGTGGGGTCCCTCACTTACACTGAGCCTAACAGCTCGGAC
CAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTC
AGGTGTGCGGTCCAGTGATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGA
TCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTC
AACAACACGCGGCGCGCGGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACT
GGGTTACCAAGACGTGTGGGGGCCCCCGTGCAACATCGGGGGGGCGCGCAACAAC
ACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGGCCACCTACGCCAGAT
GCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGG
CACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCG

Fig. 21J

TGGAGCACAGGTTTGAAGCCGCATGCAATTGGACTCSAGGAGAGCGTTGTGACTTGGA
GGACAGGGATAGATCAGAGCTTAGCCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATA
CTGCCCTGTTCTTCACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCA
GAACATCGTGGACGTGCAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTC
ATCAAATGGGAGTATGTCCTGTTGCTCTTCCTTCTCCTGGCAGACGCGCGCATCTGCGC
CTGCTTATGGATGATGCTGCTGATAGCTCAAGCTGAGGGCCGCTTAGAGAACCTGGTG
GTCCTCAATGCGGGCGCCGTGGCCGGGGCGCATGGCACTCTTCTCTCTTGTGTTCTT
CTGTGCTGCCTGGTACATCAAGGGCAGGCTGGTCCCTGGTGGGCATACGCCCTTCTAT
GGCGTGTGGCCGCTGCTCCTGCTTCTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAA

SEQ ID NO 47 (HCC165)

AATTTGGGTAAGGTCATCGATACCCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACATATGCAACAGGGAAATTTGCCCGGTTGCTCTTTCTCT
ATCTTCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTACGAACGACTGCTCCAACTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTGCAATTTGCTCGTTGGGGCGGCTGCTTTCTG
TTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTTCTCTCTCTCCAGCTGTTCA
CCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTTGCTCAATCTATCCCGG
CCACATAACGGGTACCGTATGGCTTGGGATATGATGATGAACTGGTGCCTACAACG
GCCCTGGTGGTATCGCAGCTGCTCCGGATCCCAACAAGCTGTCGTGGACATGGTGGCGG
GGGCCCCATTGGGGAGTCTTGGCGGGCCCTCGCCTACTATTCCATGGTGGGGAACTGGGC
TAAGGTTTTGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGTGTCAG
GAGGGGCAGCAGCCTCCGATACCAGGGGCCCTTGTGTCCCTCTTTAGCCCCGGGTCCGC
TCAGAAAATCCAGCTCCTAAACACCAACGGCAGTTGGCACATCAACAGGACTGCCCT
GAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAACACAAA
TTCAACTCGTCTGGATGCCAGAGCGCTTGGCCAGCTGTGCTCCATCGACAAGTTCC
CTCAGGGGTGGGGTCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGGCCCTA
CTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGT
CCAGTGTATTGCTTACCCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTTTTGGTGT
CCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAACACGCGG
CCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTACCAAGA
CGTGTGGGGGGCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTTGACCTGCC

Fig. 21K

CCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTCTGGGCC
CTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTACCCCTGCA
CTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGCACAGGTT
CGAAGCCGCATGCAATTGGA CTGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAG
ATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATACTGCCCTGTTCC
TTCACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAACATCGTGG
ACGTGCAATACCTGTACGGTGTAGGGTGGGCGGTTGTCTCCCTTGTCAATGGA
GTATGTCTGTGCTCTTCTCTCTGCGCAGACGCGCGCATCTGCCCTGCTTATGGA
TGATGCTGCTGATAGCTCAAGCTGAGGCCGCTTAGAGAACCTGGTGGTCTCAATGC
GGCGGCGGTGGCGGGGGCGCATGGCACTCTTCTCTCTGTGTTCTCTGTGCTGCCT
GGTACATCAAGGGCAGGCTGGTCCCTGGTGGCGCATACGCCCTCTATGGCGTGTGGCC
GCTGCTCTGCTTCTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAAGCTT

SEQ ID NO 49 (HCC168)

ATGAGCACGAATCCTAAACCTCAAAGAAAAACCAAACGTAACACCAACCGCCGCCCA
CAGGACGTCAAGTTCCTGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGC
GCAGGGGGCCCCAGGTTGGGTGTGCGCGCGACTAGGAAGACTTCCGAGCGGTGCAAC
CTCGTGGGAGGCGACAACCTATCCCCAAGGCTCGCCGACCCGAGGGTAGGGCCTGGG
CTCAGCCCGGGTACCCTTGGCCCTCTATGGCAATGAGGGCATGGGGTGGGCAGGATG
GCTCCTGTACCCCGCGGTCTCGGCCTAGTTGGGGCCCTACAGACCCCGGGCGTAGG
TCGCGTAATTTGGGTAAAGGTGATCGATACCTTACATGCGGCTTCGCCGACCTCGTGG
GGTACATTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGG
CGTCCGGGTTCTGGAGGACGGCGTGAACATATGCAACAGGGAAATTTGCCCGGTTGCTCT
TTCTCTATCTTCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCCGCTTATGAA
GTGCGCAACGTGTCCGGGATGTACCATGTACGAACGACTGCTCCAACCTCAAGCATTG
TGTATGAGGCAGCGGACATGATCATGCACACCCCGGGTGGTGGCCCTGCGTTCCGGGA
GAACAACCTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCC
AGCGTCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTT
TCTGTTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTTCTCTGCTCTCCAGCTG
TTCACCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATC
CCGGCCACATAACGGGTACCGTATGGCTTGGGATATGATGATGAACTGGTGGCCTAC
AACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCCAAGCTGTGCTGGACATGGTG
GCGGGGGCCCCATTGGGGAGTCTGGCGGGCCTCGCCTACTATTCATGGTGGGGAACT
GGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGT
GTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGG

Fig. 21L

TCGGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACT
GCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAAC
ACAAATTCAACTCGTCTGGATGCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAA
GTTGCTCAGGGGTGGGTCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGG
CCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGT
GCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTT
TGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAAC
ACGCGGCCCGCGGAGGCAACTGGTTGCGCTGTACATGGATGAATGGCACTGGGTTCA
CCAAGACGTGTGGGGGCCCGCGTGAACATCGGGGGGGCGGCAACAACACCTTGA
CCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGGCCACCTACGCCAGATGCGGTTCT
TGGGGCCCTGGCTGACACCTAGGTGTATGGTTTCATTACCCATATAGGCTCTGGCACTAC
CCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGC
ACAGGTTCSAAGCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACA
GGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATACTGCC
CTGTTCCCTTCACCAACCTGCGGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAAC
ATCGTGGACGTGCAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCAATCA
AATGGGAGTATGTCCTGTTGCTCTTCTCTCTGCGAGACGCGCGCATCTGCGCCTGC
TTATGGATGATGCTGCTGATAGCTCAAGCTGAGGCGCGCTTAGAGAACCTGGTGGTCC
TCAATGCGGCGGCGCGTGGCGGGGCGCATGGCACTCTTCTCTCTGTTGTTCTTCTGT
GCTGCCTGGTACATCAAGGGCAGGCTGGTCCCTGGTGGCGCATACGCCTTCTATGGCG
TGTGGCGGCTGCTCCTGCTTCTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAA

Fig. 22

OD measured at 450 nm
construct

| Fraction | volume | dilution | 39 Type 1b | 40 Type 1b | 62 Type 3a | 63 Type 5a |
|--------------|--------|----------|------------------|------------------|------------------|------------------|
| START | 23 ml | 1/20 | 2.517 | 1.954 | 1.426 | 1.142 |
| FLOW THROUGH | 23 ml | 1/20 | 0.087 | 0.085 | 0.176 | 0.120 |
| 1 | 0.4 ml | 1/200 | 0.102 | 0.051 | 0.048 | 0.050 |
| 2 | | | 0.396 | 0.550 | 0.090 | 0.067 |
| 3 | | | 2.627 | 2.603 | 2.481 | 2.372 |
| 4 | | | 3 | 2.967 | 3 | 2.694 |
| 5 | | | 3 | 2.810 | 2.640 | 2.154 |
| 6 | | | 2.694 | 2.499 | 1.359 | 1.561 |
| 7 | | | 2.408 | 2.481 | 0.347 | 1.390 |
| 8 | | | 2.176 | 1.970 | 1.624 | 0.865 |
| 9 | | | 1.461 | 1.432 | 0.887 | 0.604 |
| 10 | | | 1.236 | 0.926 | 0.543 | 0.519 |
| 11 | | | 0.981 | 0.781 | 0.294 | 0.294 |
| 12 | | | 0.812 | 0.650 | 0.249 | 0.199 |
| 13 | | | 0.573 | 0.432 | 0.239 | 0.209 |
| 14 | | | 0.653 | 0.371 | 0.145 | 0.184 |
| 15 | | | 0.441 | 0.348 | 0.151 | 0.151 |
| 16 | | | 0.321 | 0.374 | 0.098 | 0.106 |
| 17 | | | 0.525 | 0.186 | 0.099 | 0.108 |
| 18 | | | 0.351 | 0.171 | 0.083 | 0.090 |
| 19 | | | 0.192 | 0.164 | 0.084 | 0.087 |




Fig. 23

Figure 24

| Fraction | volume | dilution | OD measured at 450 nm | | | |
|----------|-------------|----------|-----------------------|------------------|------------------|------------------|
| | | | construct | | | |
| | | | 39 Type 1b | 40 Type 1b | 62 Type 3a | 63 Type 5a |
| 20 | 250 μ l | 1/200 | 0.072 | 0.130 | 0.096 | 0.051 |
| 21 | | | 0.109 | 0.293 | 0.084 | 0.052 |
| 22 | | | 0.279 | 0.249 | 0.172 | 0.052 |
| 23 | | | 0.093 | 0.151 | 0.297 | 0.054 |
| 24 | | | 0.080 | 0.266 | 0.438 | 0.056 |
| 25 | | | 0.25 | 0.100 | 0.457 | 0.048 |
| 26 | | | 3 | 1.649 | 0.722 | 0.066 |
| 27 | | | 3 | 3 | 2.526 | 0.389 |
| 28 | | | 3 | 3 | 3 | 2.345 |
| 29 | | | 3 | 3 | 2.349 | 2.580 |
| 30 | | | 2.227 | 1.921 | 1.424 | 1.333 |
| 31 | | | 0.263 | 0.415 | 0.356 | 0.162 |
| 32 | | | 0.07 | 0.172 | 0.154 | 0.064 |
| 33 | | | 0.103 | 0.054 | 0.096 | 0.057 |
| 34 | | | 0.045 | 0.045 | 0.044 | 0.051 |
| 35 | | | 0.043 | 0.047 | 0.045 | 0.046 |
| 36 | | | 0.045 | 0.045 | 0.049 | 0.040 |
| 37 | | | 0.045 | 0.047 | 0.046 | 0.048 |
| 38 | | | 0.046 | 0.048 | 0.047 | 0.057 |
| 39 | | | 0.045 | 0.048 | 0.050 | 0.057 |
| 40 | | | 0.046 | 0.049 | 0.048 | 0.049 |




Fig. 25

Figure 1 consists of 15 sub-diagrams labeled (a) through (m), arranged vertically. Each diagram shows a different stage in the construction of a 3D model of a human head and neck. The process begins with a simple wireframe (a) and gradually adds more detail, including facial features, hair, and clothing, until it reaches a fully rendered, textured model (m). The diagrams are arranged in a vertical column, with each subsequent diagram building upon the previous one.




Fig. 26




Fig.27




Fig.28

M 1 2 3 4 5 6

67 kD -

45 kD -

29 kD -

18 kD -

14 kD -


Fig.29

Lane 1: Crude Lysate
 Lane 2: Flow through Lentil Chromatography
 Lane 3: Wash with EMPIGEN Lentil Chromatography
 Lane 4: Eluate Lentil Chromatography
 Lane 5: Flow through during concentration lentil eluate
 Lane 6: Pool of E1 after Size Exclusion Chromatography

NON - REDUCED

Fig. 31A

E2 + CONTAMINANTS (AGGREGATES)



REDUCED






Fig. 31B

Fig. 32




SILVER STAIN OF PURIFIED E2



1. 30 mM IMIDAZOLE WASH Ni-IMAC
2. 0.5 ug E2

Fig.33



| No. | Ret. (ml) | Peak start (ml) | Peak end (ml) | Dur (ml) | Area (ml*AU) | Height (mAU) |
|-----|--------------|--------------------|------------------|-------------|-----------------|-----------------|
| 1 | -0.45 | -0.46 | -0.43 | 0.04 | 0.0976 | 4.579 |
| 2 | 1.55 | 0.75 | 3.26 | 2.51 | 796.4167 | 889.377 |
| 3 | 3.27 | 3.26 | 3.31 | 0.05 | 0.0067 | 0.224 |
| 4 | 3.35 | 3.32 | 3.33 | 0.02 | 0.0002 | 0.018 |

Total number of detected peaks = 4
 Total Area above baseline = 0.796522 ml*AU
 Total area in evaluated peaks = 0.796521 ml*AU
 Ratio peak area / total area = 0.999999
 Total peak duration = 2.613583 ml

Fig. 34




Fig. 35A-1




Fig. 35A-2




Fig. 35A-3




Fig. 35A-4




Fig. 35A-5




Fig. 35A-6




Fig. 35A-7




Fig. 35A-8




Fig. 35B-1




Fig. 35B-2




Fig. 35B-3




Fig. 35B-4




Fig. 35B-5




Fig. 35B-6




Fig. 35B-7




Fig. 35B-8

Fig. 36A

E1 Ab




Fig. 36B

E2 Ab




Fig. 37A

Non Responders




Fig. 37B

Long Term Responders




Fig. 37C

Type 1b




Fig. 37D

Type 3a




Fig. 39

PARTIAL DEGLYCOSYLATION OF HCV E1 ENVELOPE PROTEIN

Endoglycosidase H
(Endo H)

0m
0.6m
0.9m
0.9m
0.6m
0.9m
0.6m
0.9m
0.4m
4m
40m
400m

| 6 | 5 | 4 | 3 | 2 | 1 | 0 |
|---------|--------|--------|--------|--------|--------|---|
| - 106.0 | - 80.0 | - 49.5 | - 32.5 | - 27.5 | - 18.5 | |

PARTIAL TREATMENT OF HCV E2/E2s ENVELOPE PROTEINS BY PNGase F




Fig. 40

Fig. 41 *In Vitro* Mutagenesis of HCV E1 glycoprotein






Fig. 42A *In Vitro* Mutagenesis of HCV E1 glycoprotein





1. First step of PCR amplification (Gly-# and Ovr-# primers)



2. Overlap extension and nested PCR

Fig. 42B

a. Overlap extension



b. Nested PCR amplification (GPT-2 and TKr-2 primers)






Fig. 43 *In Vitro* Mutagenesis of IICV E1 glycoprotein






Fig. 44A



Fig. 44B



Fig.45

KDa 119 67 43 29 18

| | | | |



Fig.46

Fig. 47

| | age (years) | HCV infection (years) | genotype |
|--------|----------------|--------------------------|----------|
| Marcel | 17 | 9 | 1a |
| Peggy | 21 | 16.5 | 1b |
| Fenna | 15 | 9 | 1a |
| Yoran | 12 | none | |
| Marti | 12 | none | |

chronic carriers (strong T-cell adjuvant)


↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ 50 µg E1 dose
 0 3 6 9 12 15 26 29 32 35 38 41 weeks

naive (alum)

↓ ↓ ↓ ↓ ↓ ↓ 50 µg E1 dose
 0 3 6 9 12 15 weeks

Fig. 48


48a



48b



48c



48d





Fig. 49



1 Fem m a, 2 Marcel, 3 P eggy






Fig. 50






Fig 51





Fig 52

[illegible]

vaccinated



controls

